Related Experiment Video

Updated: Aug 8, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer

Ulrich Gatzemeier1

  • 1Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany.

Oncology (Williston Park, N.Y.)
|December 20, 2003
PubMed

Insights

Novel targeted therapies, including HER1/epidermal growth factor receptor (EGFR) inhibitors like gefitinib and erlotinib, show promise for improving outcomes in non-small-cell lung cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Non-small-cell lung cancer (NSCLC) presents a significant global health challenge with limited survival improvements from traditional chemotherapy.
  • Targeted therapies offer a promising avenue for enhancing patient management and treatment efficacy in advanced NSCLC.

Purpose of the Study:

  • To review the role and potential of novel targeted therapies, specifically HER1/epidermal growth factor receptor (EGFR) inhibitors, in managing advanced non-small-cell lung cancer.
  • To highlight the clinical evaluation of gefitinib and erlotinib, including combination strategies with bevacizumab.

Main Methods:

  • Review of current literature and clinical trial data on HER1/EGFR inhibitors in NSCLC.
  • Examination of gefitinib's approved use and erlotinib's ongoing phase III evaluations.

Main Results:

  • Gefitinib (Iressa) is approved for advanced, refractory NSCLC.
  • Erlotinib (Tarceva) is under investigation as first-line combination therapy and as monotherapy, and in combination with bevacizumab (Avastin).

Conclusions:

  • HER1/EGFR inhibitors represent a significant advancement in NSCLC treatment.
  • Ongoing trials with erlotinib and combination therapies are crucial for optimizing the use of targeted agents and improving patient survival in non-small-cell lung cancer.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...